Deerfield To NitroMed: Not So Fast, Not So Cheap

NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet